Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA
Walton SM, Schumock GT, McLain DA

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details
Walton SM, Schumock GT, McLain DA. Cost analysis of flavocoxid compared to naproxen for management of mild to moderate OA. Current Medical Research and Opinion 2010; 26(9) : 2253-2261

DOI
10.1185/03007995.2010.505545

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Aged, 80 and over; Algorithms; Anti-Inflammatory Agents, Non-Steroidal /adverse effects /economics /therapeutic use; Catechin /adverse effects /economics /therapeutic use; Comorbidity; Costs and Cost Analysis; Drug Combinations; Hospitalization /economics /statistics & numerical data; Humans; Models, Economic; Naproxen /adverse effects /economics /therapeutic use; Osteoarthritis /drug therapy /economics /epidemiology; Severity of Illness Index

AccessionNumber
22010001578

Date bibliographic record published
22/12/2010